As of 2026-03-14, the EV/EBITDA ratio of Trillium Therapeutics Inc (TRIL.TO) is -43.38. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TRIL.TO's latest enterprise value is 2,480.54 mil CAD. TRIL.TO's TTM EBITDA according to its financial statements is -57.19 mil CAD. Dividing these 2 quantities gives us the above TRIL.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.7x - 33.8x | 21.8x |
| Forward P/E multiples | 7.8x - 26.4x | 17.1x |
| Fair Price | (5.57) - (17.20) | (12.35) |
| Upside | -123.9% - -173.7% | -153.0% |
| Date | EV/EBITDA |